---
title: hepatitis C virus recommended First-Line Oral Direct-Acting Antiviral  DAA  Regimens
---

# hepatitis C virus recommended First-Line Oral Direct-Acting Antiviral (DAA) Regimens

> 有 cirrhosis, 只能用 Sofo and Glec

- Sofosbuvir & velpatasvir

  - Genotypes 1-6, 12 weeks Rx

- Glecaprevir & pibrentasvir

  - Gentotypes 1-6; 8 weeks Rx

- Simplified treatment:

  - adults w/ HCV
  - w/o cirrhosis or
  - w/ compensated cirrhosis & no prior HCV treatment;
  - cannot have HIV, HBsAg ⊕, pregnancy, HCC, ESRD, or liver transplant;

- if decompensated or previously treated, refer to GI for assistance.

## Based on Hepatology 2020;71:686

- Antiviral classes:
  - RNA polymerase inhibitor (“…buvir”);
  - NS5a inhibitor (“…asvir”);
  - NS3/4A protease inhibitor (“…previr”).

---

![Figure: ](https://i.imgur.com/eBA9L0Q.png)

---

#### 換句話說

1. Harvoni:

- Active ingredients: Ledipasvir and Sofosbuvir
- Used for: Treating hepatitis C genotype 1, 4, 5, and 6
- Treatment duration: Typically 12 weeks
- It is usually well-tolerated, with common side effects including headache, fatigue, and nausea.

2. Maviret:

- Active ingredients: Glecaprevir and Pibrentasvir
- Used for: Treating all major genotypes of hepatitis C (1-6)
- Treatment duration: 8 to 16 weeks, depending on the patient's prior treatment history and liver disease stage
- It has a high cure rate (>95%) and is generally well-tolerated, with common side effects being headache, fatigue, and nausea.

3. Epclusa:

- Active ingredients: Sofosbuvir and Velpatasvir
- Used for: Treating all major genotypes of hepatitis C (1-6)
- Treatment duration: Typically 12 weeks
- It has a high cure rate (>95%) and is generally well-tolerated, with common side effects being headache, fatigue, and nausea.

Choosing the appropriate medication depends on the patient's genotype, treatment history, liver disease stage, and the presence of any other medical conditions. Patients should consult their healthcare providers to determine which option is best for their specific situation.
